Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Fry

Showing results (721-730 of 737) with videos related to

Pageof 74
Sort By:
The Journal of Clinical Investigation|September 14, 2020
Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patientsKazusa Ishii, Marie Pouzolles, Christopher D Chien, et al.
Nature Medicine|November 21, 2017
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapyTerry J Fry, Nirali N Shah, Rimas J Orentas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2020
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell TrialNirali N Shah, Steven L Highfill, Haneen Shalabi, et al.
Journal for Immunotherapy of Cancer|June 5, 2026
CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial resultsSara K Silbert, Flavia Gava, Bonnie Yates, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 22, 2018
Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single InstitutionRicardo Melendez-Munoz, Rachel Marchalik, Theresa Jerussi, et al.
Nature Medicine|October 3, 2018
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cellMarco Ruella, Jun Xu, David M Barrett, et al.
Journal for Immunotherapy of Cancer|December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse eventsMarcela V Maus, Sara Alexander, Michael R Bishop, et al.
Blood|September 15, 2021
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cellsDaniel A Lichtenstein, Fiorella Schischlik, Lipei Shao, et al.
The Review of Scientific Instruments|June 1, 2015
A slow neutron polarimeter for the measurement of parity-odd neutron rotary powerW M Snow, E Anderson, L Barrón-Palos, et al.
Blood|May 23, 2022
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CARHaneen Shalabi, Haiying Qin, Angela Su, et al.
Pageof 74

Showing results (721-730 of 737) with videos related to

Sort By:
Pageof 74
The Journal of Clinical Investigation|September 14, 2020
Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patientsKazusa Ishii, Marie Pouzolles, Christopher D Chien, et al.
Nature Medicine|November 21, 2017
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapyTerry J Fry, Nirali N Shah, Rimas J Orentas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2020
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell TrialNirali N Shah, Steven L Highfill, Haneen Shalabi, et al.
Journal for Immunotherapy of Cancer|June 5, 2026
CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial resultsSara K Silbert, Flavia Gava, Bonnie Yates, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 22, 2018
Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single InstitutionRicardo Melendez-Munoz, Rachel Marchalik, Theresa Jerussi, et al.
Nature Medicine|October 3, 2018
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cellMarco Ruella, Jun Xu, David M Barrett, et al.
Journal for Immunotherapy of Cancer|December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse eventsMarcela V Maus, Sara Alexander, Michael R Bishop, et al.
Blood|September 15, 2021
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cellsDaniel A Lichtenstein, Fiorella Schischlik, Lipei Shao, et al.
The Review of Scientific Instruments|June 1, 2015
A slow neutron polarimeter for the measurement of parity-odd neutron rotary powerW M Snow, E Anderson, L Barrón-Palos, et al.
Blood|May 23, 2022
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CARHaneen Shalabi, Haiying Qin, Angela Su, et al.
Pageof 74